(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Introduction International guidelines emphasise the role of heart valve centres (HVC) and specialist heart valve clinics ...

A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part. Survival ...

The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain. In this trial involving ...

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial ...

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced ...

Correspondence to Dr Parco M Siu, The University of Hong Kong, Hong Kong, 999077, Hong Kong; pmsiu{at}hku.hk Data sources Embase, MEDLINE, PsycINFO, Cochrane Library, Web of Science, Scopus and ...

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health ...

Drugs like semaglutide, the active ingredient of Ozempic and Wegovy, are more effective in treating type 2 diabetes than conventional treatments, a comprehensive new comparative study finds. About one ...

HyBryte demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ...